Patents by Inventor Daniel Pennington

Daniel Pennington has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immune modulation via C-type lectin
    Patent number: 9205153
    Abstract: The invention relates to the regulation of the immune system, and in particular to the finding that the CLEC9a molecule is a marker for dendritic cells which are capable of cross-presenting extracellular antigens via the MHC class I pathway. This makes them particularly suitable for generation of cytotoxic T lymphocyte responses. Materials and methods are provided both for the induction of immune responses against target antigens, and for the inhibition or suppression of undesirable immune responses in which these cells are involved.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: December 8, 2015
    Assignee: Cancer Research Technology Limited
    Inventors: David Sancho-Madrid, Oliver Schulz, Neil Charles Rogers, Caetano Reis e Sousa, Olivier Pierre Joffre, Daniel Pennington
  • Immune Modulation Via C-Type Lectin
    Publication number: 20140328865
    Abstract: The invention relates to the regulation of the immune system, and in particular to the finding that the CLEC9a molecule is a marker for dendritic cells which are capable of cross-presenting extracellular antigens via the MHC class I pathway. This makes them particularly suitable for generation of cytotoxic T lymphocyte responses. Materials and methods are provided both for the induction of immune responses against target antigens, and for the inhibition or suppression of undesirable immune responses in which these cells are involved.
    Type: Application
    Filed: October 9, 2013
    Publication date: November 6, 2014
    Applicant: Cancer Research Technology Limited
    Inventors: David Sancho-Madrid, Oliver Schulz, Neil Charles Rogers, Caetano Reis e Sousa, Olivier Pierre Joffre, Daniel Pennington
  • Immune modulation via C-type lectin
    Patent number: 8580266
    Abstract: The invention relates to the regulation of the immune system, and in particular to the finding that the CLEC9a molecule is a marker for dendritic cells which are capable of cross-presenting extracellular antigens via the MHC class I pathway. This makes them particularly suitable for generation of cytotoxic T lymphocyte responses. Materials and methods are provided both for the induction of immune responses against target antigens, and for the inhibition or suppression of undesirable immune responses in which these cells are involved.
    Type: Grant
    Filed: July 21, 2008
    Date of Patent: November 12, 2013
    Assignee: Cancer Research Technology Limited
    Inventors: David Sancho-Madrid, Oliver Schulz, Neil Charles Rogers, Caetano Reis E Sousa, Olivier Pierre Joffre, Daniel Pennington
  • IMMUNE MODULATION VIA C-TYPE LECTIN
    Publication number: 20100221265
    Abstract: The invention relates to the regulation of the immune system, and in particular to the finding that the CLEC9a molecule is a marker for dendritic cells which are capable of cross-presenting extracellular antigens via the MHC class I pathway. This makes them particularly suitable for generation of cytotoxic T lymphocyte responses. Materials and methods are provided both for the induction of immune responses against target antigens, and for the inhibition or suppression of undesirable immune responses in which these cells are involved.
    Type: Application
    Filed: July 21, 2008
    Publication date: September 2, 2010
    Inventors: David Sancho-Madrid, Oliver Schulz, Neil Charles Rogers, Caetano Reis E. Sousa, Olivier Pierre Joffre, Daniel Pennington